Brief: Fulcrum Therapeutics Q3 Basic EPS USD -0.39
07/11/2023 12:00
Nov 07 (Reuters) - Fulcrum Therapeutics Q3 operating expenses USD 28.199 million. * Q3 operating income USD -27.44 million * Q3 net income USD -24.017 million * Q3 collaboration revenue USD 759 thousand
Recent news on Fulcrum Therapeutics
See all newsFulcrum Therapeutics, Inc. expected to post a loss of 14 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE - Nvidia, Gold miners, Nike
U.S. STOCKS ON THE MOVE - Sunrun, JetBlue Airways, Dell Technologies
U.S. STOCKS ON THE MOVE - KBR, Vista Energy, Fulcrum Therapeutics
Fulcrum to merge with Slate in all-stock deal after drug setback